← Back to your selection

Catalio Capital Management

Activity from announced rounds

Activity in this selectionbelvedere-trading-f14c94b7
Rounds participated in
10
Confirmed lead rounds
1
6 roles undisclosed
New companies
10
First participation on record · 0 follow-on
Funding in participating rounds
$1.2B
10 disclosed · full round size, not this investor’s share

By stage

Series C+5
Series B3
Growth1
Undisclosed1

By primary sector

Biotech6
Healthtech4

By country

United States8
Australia1
United Kingdom1

Rounds

10 in this selection
BigHat Biosciences

An AI and synthetic-biology platform that designs and engineers antibody therapeutics.

$75MSeries C
Participant
Basecamp Research

Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines.

$140MSeries C
Participant
Evvy

Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.

$40MSeries B
Lead
Superluminal Medicines

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries B
Participant
Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C
Role not disclosed
AdvanCell

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D
Role not disclosed
9amHealth

AI-enabled virtual specialty care platform for managing high-cost chronic conditions

$26MSeries B
Role not disclosed
Imperative Care

Develops treatments for patients suffering from thromboembolic disease

$100MGrowth
Role not disclosed
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F
Role not disclosed